AbbVie Inc (ABBV)vsAscendis Pharma AS (ASND)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
ASND
Ascendis Pharma AS
$263.52
+0.87%
HEALTHCARE · Cap: $17.75B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 6049% more annual revenue ($64.39B vs $1.05B). ASND leads profitability with a 70.9% profit margin vs 9.8%. ASND trades at a lower P/E of 20.9x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
ASND
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Intrinsic value data unavailable for ASND.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Every $100 of equity generates 53 in profit
Keeps 71 of every $100 in revenue as profit
Strong operational efficiency at 65.0%
Revenue surging 114.7% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Trading at 10.4x book value
0.0% earnings growth
Weak financial health signals
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : ASND
The strongest argument for ASND centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 70.9% and operating margin at 65.0%. Revenue growth of 114.7% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : ASND
The primary concerns for ASND are Price/Book, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while ASND is a growth play — different risk/reward profiles.
ASND carries more volatility with a beta of 0.48 — expect wider price swings.
ASND is growing revenue faster at 114.7% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 61/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Ascendis Pharma AS
HEALTHCARE · BIOTECHNOLOGY · USA
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?